Project Details
Description
PROJECT SUMMARY/ABSTRACT
The problem: Patients suffering from chronic pancreatitis (CP) have a higher risk of pancreatic ductal
adenocarcinoma (PDAC). CP is characterized by an activated pancreatic stellate cell (PaSC)-rich stroma, which
has facilitated the progression of non-invasive PanIN lesions to invasive PDAC. A critical barrier to progress
in preventing the CP-to-PDAC transition is the gap of knowledge regarding the mechanism by which quiescent
PaSCs become activated by inflammatory mediators, expand, and synthesize stroma and matrix
metalloproteinases (MMPs), facilitating the progression of non-invasive PanIN lesions to invasive PDAC. Among
the inflammatory mediators of CP are reactive oxygen species (ROS), which activate PaSCs. ROS generation
can occur as a primary product of NADPH oxidase (Nox) enzymes. Previously, we showed that Nox1 signaling
in CP-activated PaSCs: i) forms fibrotic tissue, ii) up-regulates both the transcription factor E-cadherin repressor
Twist1 and MMP-9, and iii) facilitates the invasion of pancreatic cancer cell lines both in vitro and in vivo. The
objective: To address the gaps in our knowledge regarding the mechanisms by which Nox1/Twist1/MMP-9
signaling in CP-activated PaSCs facilitates the progression of non-invasive PanIN lesions to invasive PDAC.
The central hypothesis: The induction of CP generates ROS by Nox1 in PaSCs, which lead to a sustained
expression of Twist1. Twist1, in turn, induces the expression of MMP-9, which promotes the progression of non-
invasive PanIN lesions to invasive PDAC by degrading the basal lamina. The hypothesis will be tested by
pursuing two specific aims: 1) Under the first aim, we will test in vitro the prediction that inhibiting
Nox1/Twist1/MMP-9 signaling in CP-activated PaSCs attenuates the degradation of collagen IV and laminin.
Under the second aim, we will test in vivo the prediction that inhibiting Nox1 signaling in CP-activated PaSCs
prevents the progression of non-invasive PanIN lesions to invasive PDAC by attenuating the degradation of
basal lamina. Our outcomes will include 1) new knowledge of CP-related mechanisms of progression of PDAC,
2) new knowledge of Nox1-related mechanisms of progression of PDAC, 3) high impact research experiences
for undergraduate students. The approach is innovate because it will assess the extent to which the generation
of Nox1-derived ROS from CP-activated PaSCs can facilitate the progression of non-invasive PanIN lesions to
invasive PDAC. The proposed research is significant because a finding that the lack of Nox1 in CP-activated
PaSCs prevents the progression of PanIN lesions to invasive PDAC by attenuating the degradation of basal
lamina will establish the feasibility and premise for future translational research directed at developing rational,
stroma-targeted therapies of
early-stages of
PDAC (e.g.,
carcinoma in situ)
that, in combination with other
approaches might lead to clinical strategies to increase the survival of patients. Moreover, these studies are
designed to promote opportunities for a diverse undergraduate student participation providing them with
exposure to hands-on experiments and close mentoring.
Status | Active |
---|---|
Effective start/end date | 8/1/22 → 7/31/25 |
Funding
- National Cancer Institute: $444,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.